神经变性遗传疾病print.ppt

* * * * * * Figure 1. Schematic Illustration of the Three Primary End Points of the Study. The three primary end points, which had to be met in a hierarchical fashion to declare positive results, are shown. The green arrows indicate the first end point: the superiority of early-start treatment versus placebo with respect to the estimate of the rate of change from baseline in the total Unified Parkinson’s Disease Rating Scale (UPDRS) score between weeks 12 and 36. The red arrow indicates the second end point: the superiority of early-start treatment versus delayed-start treatment with respect